Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021

Rhea-AI Summary

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced that its executives will participate in two investor conferences in August 2021. George Lasezkay and Thomas A. Ciulla will speak at the Wedbush PacGrow Healthcare Virtual Conference on August 11 at 9:45 am ET, discussing Goldeneye. They will also participate in the H.C. Wainwright Ophthalmology Virtual Conference on August 17 at 12:00 pm ET, addressing Vision Repair Beyond Traditional Anti-VEGF Therapy. Archived webcasts will be available for three months on the Clearside website.

ALPHARETTA, Ga., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in two upcoming investor conferences in August 2021:

Wedbush PacGrow Healthcare Virtual Conference
Panel Discussion: Goldeneye
Wednesday, August 11, 2021 at 9:45 am ET

H.C. Wainwright Ophthalmology Virtual Conference
Panel Discussion: Vision Repair Beyond Traditional Anti-VEGF Therapy
Tuesday, August 17, 2021 at 12:00 pm ET
Corporate Presentation available Tuesday, August 17, 2021 at 7:00 am ET

A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector^® targets the suprachoroidal space (SCS^®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical participate in the Wedbush PacGrow Healthcare Virtual Conference?

Clearside Biomedical will participate in the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 9:45 am ET.

What topic will Clearside Biomedical discuss at the H.C. Wainwright Ophthalmology Virtual Conference?

At the H.C. Wainwright Ophthalmology Virtual Conference, Clearside Biomedical will discuss 'Vision Repair Beyond Traditional Anti-VEGF Therapy' on August 17, 2021, at 12:00 pm ET.

Where can I find the archived webcasts of Clearside Biomedical's investor conferences?

Archived webcasts of Clearside Biomedical's investor conferences can be found on their website under the Investors section for three months.

Who will represent Clearside Biomedical at the upcoming investor conferences?

George Lasezkay, President and CEO, and Thomas A. Ciulla, Chief Medical Officer and Chief Development Officer, will represent Clearside Biomedical.

What is the primary focus of Clearside Biomedical?

Clearside Biomedical focuses on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases.